參考文獻 |
Chapter 1
1. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G.; Lasagna, L., Cost of innovation in the pharmaceutical industry. J. Health Econ 1991, 10 (2), 107-142.
2. Cardinal, L. B., Technological innovation in the pharmaceutical industry: the use of organizational control in managing research and development. Organization Science 2001, 12 (1), 19-36.
3. Fink, C., Patent protection, Transnational corporations, and market structure: a simulation study of the Indian pharmaceutical industry. J. Ind Compet Trade 2001, 1 (1), 101-121.
4. Scherer, F. M., Pricing, profits, and technological progress in the pharmaceutical industry. J. Econ Perspect. 1993, 7 (3), 97-115.
5. Caves, R. E.; Whinston, M. D.; Hurwitz, M. A.; Pakes, A.; Temin, P., Patent expiration, entry, and competition in the U.S. pharmaceutical industry. The Brookings Papers on Economic Activity: Microeconomics. 1991, 1991, 1-66.
6. Vinatoru, M.; Toma, M.; Mason, T. J., Advances in Sonochemistry. 1st Ed.; JAI Press Inc., Connecticut, 1999; Vol. 5, pp 209-248.
7. Dondorp, A.; Nosten, F.; Stepniewska, K.; Day, N.; White, N., Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005, 366 (9487), 717-725.
8. Hay, C. A.; Anderson, L. A.; Roberts, M. F.; Phillipson, J. D., In vitro cultures of Cinchona species. Plant Cell Rep.1986, 5 (1), 1-4.
9. Gaisford, S.; O’Neill, A. A. M. Pharmaceutical Isothermal Calorimetry. 1st Ed.; Informa Healthcare USA Inc., New York, 2006; Chapter 5, pp 217-248.
10. Venkatesh, S.; Lipper, R. A., Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 2000, 89 (2), 145-154.
11. Cruciani, G.; Pastor, M.; Guba, W., VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 2000, 11, Supplement 2, S29-S39.
12. Fuster, V.; Sweeny, J. M., Aspirin: a historical and contemporary therapeutic overview. Circulation 2011, 123 (7), 768-778.
13. Mahdi, J. F.; Mahdi, A. J.; Bowen, I. D.; Bowen, I. D., The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif. 2006, 39 (2), 147-155.
14. Lyons, E., Organic mercury compound. US patent 1663204, 1928.
15. Chain, E.; Florey, H. W.; Adelaide, M. B.; Gardner, A. D.; Heatley, N. G.; Jennings, M. A.; Orr-Ewing, J.; Sanders, A. G., Penicillin as a chemotherapeutic agent. Lancet. 1940, 236 (6104), 226-228.
16. Gardner, A. D., Morphological effects of penicillin on bacteria. Nature 1940, 146 (3713), 837-838.
17. Watson, J. D.; Crick, F. H. C., Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 1953, 171 (4356), 737-738.
18. Simon, R.; Priefer, U.; Puhler, A., A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in gram negative bacteria. Nat. Biotechnol. 1983, 1 (9), 784-791.
19. Hopwood, D. A.; Malpartida, F.; Kieser, H. M.; Ikeda, H.; Duncan, J.; Fujii, I.; Rudd, B. A. M.; Floss, H. G.; Omura, S., Production of ’hybrid’ antibiotics by genetic engineering. Nature 1985, 314 (6012), 642-644.
20. Cohen, S. N.; Chang, A. C. Y.; Boyer, H. W.; Helling, R. B., Construction of biologically functional bacterial plasmids in vitro. Proc. Natl. Acad. Sci. USA 1973, 70 (11), 3240-3244.
21. Glick, B. R.; Pasternak, J. J., Molecular Biotechnology : Principles and Applications of Recombinant DNA. 4th Ed.; ASM Press, Washington, DC, 2009; Chapter 3. pp 47-97.
22. Fodor, E.; Devenish, L.; Engelhardt, O. G.; Palese, P.; Brownlee, G. G.; García-Sastre, A., Rescue of influenza a virus from recombinant DNA. J. Virol. 1999, 73 (11), 9679-9682.
23. Leroy, F.; De Vuyst, L., Lactic acid bacteria as functional starter cultures for the food fermentation industry. Trends Food Sci. Tech. 2004, 15 (2), 67-78.
24. Buckel, W.; Barker, H. A., Two pathways of glutamate fermentation by anaerobic bacteria. J. Bacteriol. 1974, 117 (3), 1248-1260.
25. Fu, J.; Bailey, F. J.; King, J. J.; Parker, C. B.; Robinett, R. S. R.; Kolodin, D. G.; George, H. A.; Herber, W. K., Recent advances in the large scale fermentation of neisseria meningitidis group B for the production of an outer membrane protein complex. Nat. Biotechnol. 1995, 13 (2), 170-174.
26. Akira, M., Secretory expression of human protein in the yeast pichia pastoris by controlled fermentor culture. Recent Pat. Biotechnol. 2010, 4 (2), 153-166.
27. Williams, D. C.; van Frank, R. M.; Muth, W. L.; Burnett, J. P., Cytoplasmic inclusion bodies in Escherichia coli producing biosynthetic human insulin proteins. Science 1982, 215 (4533), 687-689.
28. Lefort, S.; Ferrara, P., Hydrophobic adsorbants for the isolation and purification of biosynthetic human growth hormone from crude fermentation mixtures. J. Chromatogr. A 1986, 361, 209-216.
29. Patra, A. K.; Mukhopadhyay, R.; Mukhija, R.; Krishnan, A.; Garg, L. C.; Panda, A. K., Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expression Purif. 2000, 18 (2), 182-192.
30. Jensen, E. B.; Carlsen, S., Production of recombinant human growth hormone in Escherichia coli: expression of different precursors and physiological effects of glucose, acetate, and salts. Biotechnol. Bioeng. 1990, 36 (1), 1-11.
31. LaForce, F. M.; Konde, K.; Viviani, S.; Préziosi, M. P., The meningitis vaccine project. Vaccine 2007, 25, Supplement 1, A97-A100.
31. Mason, H. S.; Arntzen, C. J., Transgenic plants as vaccine production systems. Trends Biotechnol. 1995, 13 (9), 388-392.
32. Vile, R. G.; Russell, S. J.; Lemoine, N. R., Cancer gene therapy: hard lessons and new courses. Gene Ther. 2000, 7 (1), 2-8.
33. Hawley, R. G.; Lieu, F. H.; Fong, A. Z.; Hawley, T. S., Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994, 1 (2), 136-138.
34. Hamburg, M. A.; Collins, F. S., The path to personalized medicine. N. Engl. J. Med. 2010, 363 (4), 301-304.
35. Weston, A. D.; Hood, L., Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J. Proteome Res. 2004, 3 (2), 179-196.
36. Ginsburg, G. S.; McCarthy, J. J., Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 2001, 19 (12), 491-496.
37. Thomas G. Medicinal Chemistry An Introduction. John Wiley & Sons, New York, 2000; Chapter 1, pp 1-28.
38. Silverman R. B. The Organic Chemistry of Drug Design and Drug Action. Academic Press, New York, 1992; Chapter 2, pp 4-50.
40. Frank, E. Paracetamol – A Curriculum Resource. Royal Society of Chemistry, London, 2002; p 5.
41. Hinz, D. C., Process analytical technologies in the pharmaceutical industry: the FDA’s PAT initiative. Anal. Bioanal.Chem. 2006, 384 (5), 1036-1042.
42. Freston, J. W.; Chiu, Y. L.; Mulford, D. J.; Ballard Ii, E. D., Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment. Pharm. Therap. 2003, 17 (3), 361-367.
43. Coté, C. J.; Cohen, I. T.; Suresh, S.; Rabb, M.; Rose, J. B.; Weldon, B. C.; Davis, P. J.; Bikhazi, G. B.; Karl, H. W.; Hummer, K. A.; Hannallah, R. S.; Khoo, K. C.; Collins, P., A comparison of three doses of a commercially prepared oral midazolam syrup in children. Anesth. Analg. 2002, 94 (1), 37-43.
44. Ichikawa, H.; Fukumori, Y.; Moji Adeyeye, C., Design of prolonged-release microcapsules containing diclofenac sodium for oral suspensions and their preparation by the Wurster process. Int. J. Pharm. 1997, 156 (1), 39-48.
45. Ito, A.; Sugihara, M., Development of oral dosage form for elderly patients: use of agar as base of rapidly disintegrating oral tablets. Chem. Pharm. Bull. 1996, 44 (11), 2132-2136.
46. Knochen, M.; Giglio, J.; Reis, B. F., Flow-injection spectrophotometric determination of paracetamol in tablets and oral solutions. J. Pharmaceut. Biomed. 2003, 33 (2), 191-197.
47. Rawas-Qalaji, M.; Estelle, F.; Simons, R.; Simons, K., Fast-disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics. AAPS PharmSciTech 2006, 7 (2), E72-E78.
48. Reisin, L. H.; Landau, E.; Darawshi, A., More rapid relief of pain with isosorbide dinitrate oral spray than with sublingual tablets in elderly patients with angina pectoris. Am. J. Cardiol. 1988, 61 (9), 2-3.
49. Choi, J. H.; Dresler, C. M.; Norton, M. R.; Strahs, K. R., Pharmacokinetics of a nicotine polacrilex lozenge. Nicotin Tob. Res. 2003, 5 (5), 635-644.
50. Timmins, P.; Cosgrove, R. F.; Delarqy, A. M., Effect of a surfactant on absorption of AM antibiotic from non-aqueous parenteral suspensions. Drug Dev. Ind. Pharm. 1986, 12 (6), 829-837.
51. Bresson, J. L.; Bader, B.; Rocchiccioli, F.; Mariotti, A.; Ricour, C.; Sachs, C.; Rey, J., Protein-metabolism kinetics and energy-substrate utilization in infants fed parenteral solutions with different glucose-fat ratios. Am. J. Clin. Nutrit. 1991, 54 (2), 370-376.
52. Kipp, J. E., The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 2004, 284 (1–2), 109-122.
53. Ohlsén, L.; Englesson, S.; Evers, H., An znaesthetic lidocaine/prilocaine cream (Emla) for epicutaneous application tested for cutting split skin grafts. Scand. J. Plast. Recons. 1985, 19 (2), 201-209.
54. Schäfer, D.; Schäfer, W., Pharmacological studies with an ointment containing menthol, camphene and essential oils for broncholytic and secretolytic effects. Arzneim.-Forsch. 1981, 31 (1), 82-86.
55. Villada, G.; Zetlaoui, J.; Revuz, J., Local blanching after epicutaneous application of EMLA cream. Dermatology 1990, 181 (1), 38-40.
56. Edelhauser, H. F.; Van Horn, D. L.; Schultz, R. O.; Hyndiuk, R. A., Comparative toxicity of intraocular irrigating solutions on the corneal endothelium. Am. J. Ophthalmol. 1976, 81 (4), 473-481.
57. Cantor, L. B.; Hoop, J.; Katz, L. J.; Flartey, K., Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure. Clin. Ther. 2001, 23 (7), 1032-1039.
58. Virtanen, H. M.; Reitamo, S.; Kari, M.; Kari, O., Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol. Scan. 2006, 84 (5), 693-695.
59. Norn, M. S., Eyelid ointment penetrating into conjunctival sac. Acta Ophthalmol 1972, 50 (2), 206-209.
60. Mahalingam, R.; Li, X.; Jasti, B. R.; Gad, S. C., Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing. John Wiley & Sons, New York, 2010; pse348, pp 267-312.
61. Marple, B.; Roland, P.; Benninger, M., Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngology- Head and Neck Surg. 2004, 130 (1), 131-141.
62. Reagan, D. R.; Doebbeling, B. N.; Pfaller, M. A.; Sheetz, C. T.; Houston, A. K.; Hollis, R. J.; Wenzel, R. P., Elimination of coincident staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann. Intern. Med. 1991, 114 (2), 101-106.
63. Mishra, P.; Talegaonkar, S., Intranasal delivery: an approach to bypass the blood brain barrier. Indian J. Pharmacol. 2004, 36 (3), 140-147.
64. Knoester, P. D.; Jonker, D. M.; Van Der Hoeven, R. T. M.; Vermeij, T. A. C.; Edelbroek, P. M.; Brekelmans, G. J.; De Haan, G. J., Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br. J. Clin. Pharmacol. 2002, 53 (5), 501-507.
65. Hardy, J. G.; Lee, S. W.; Wilson, C. G., Intranasal drug delivery by spray and drops. J. Pharm. Pharmacol. 1985, 37 (5), 294-297.
66. Stahlhofen, W.; Gebhart, J.; Heyder, J., Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am. Ind. Hyg. Assoc. J. 1980, 41 (6), 385-398a.
67. Wigley, F. M.; Londono, J. H.; Wood, S. H.; Shipp, J. C.; Waldman, R. H., Insulin across respiratory mucosae by aerosol delivery. Diabetes 1971, 20 (8), 552-556.
68. Khanna, N.; Dalby, R.; Connor, A.; Church, A.; Stern, J.; Frazer, N., Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers. Sex. Transm. Dis. 2008, 35 (6) 577-582.
69. Hussain, A.; Ahsan, F., The vagina as a route for systemic drug delivery. J. Controlled Release 2005, 103 (2), 301-313.
70. Ayres, J. W.; Lorskulsint, D.; Lock, A., Absorption of 3H-benzocaine from ointments following rectal administration in rats. J. Pharm. Sci. 1975, 64 (12), 1958-1961.
71. Winkler, H. A.; Sand, P. K., Treatment of detrusor instability with oxybutynin rectal suppositories. Int. Urogynecol. J. 1998, 9 (2), 100-102.
72. Allen, L. V., Suppositories as drug delivery systems. Journal of Pharmaceutical Care in Pain & Symptom Control 1997, 5 (2), 17-26.
73. Di Martino, P.; Guyot-Hermann, A. M.; Conflant, P.; Drache, M.; Guyot, J. C., A new pure paracetamol for direct compression: the orthorhombic form. Int. J. Pharm. 1996, 128 (1–2), 1-8.
74. Malkowska, S.; Khan, K. A., Effect of re-conpression on the properties of tablets prepared by dry granulation. Drug Dev. Ind. Pharm. 1983, 9 (3), 331-347.
75. Kleinebudde, P., Roll compaction/dry granulation: pharmaceutical applications. Eur. J. Pharm. Biopharm. 2004, 58 (2), 317-326.
76. Kristensen, H. G.; Schaefer, T., Granulation: a review on pharmaceutical wet-granulation. Drug Dev. Ind. Pharm. 1987, 13 (4-5), 803-872.
77. Faure, A.; York, P.; Rowe, R. C., Process control and scale-up of pharmaceutical wet granulation processes: a review. Eur. J. Pharm. Biopharm. 2001, 52 (3), 269-277.
78. Takano, R.; Sugano, K.; Higashida, A.; Hayashi, Y.; Machida, M.; Aso, Y.; Yamashita, S., Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm. Res. 2006, 23 (6), 1144-1156.
79. Lai, H.; Chen, Q., Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations. Plant Cell Rep. 2012, 31 (3), 573-584.
80. Hoppe, P. A.; Kochman, S. A., Rossi’s Principles of Transfusion Medicine. 4th Ed.; Wiley-Blackwell, Singapore, 2009; Chapter 64, pp 1010-1031.
81. Storer, B. E., Design and Analysis of Phase I Clinical Trials. Biometrics 1989, 45 (3), 925-937.
82. Green, S. J.; Dahlberg, S., Planned versus attained design in phase II clinical trials. Stat. Med. 1992, 11 (7), 853-862.
83. Stallard, N.; Todd, S., Sequential designs for phase III clinical trials incorporating treatment selection. Stat. Med. 2003, 22 (5), 689-703.
84. Bae, J. P., Drug patent expirations and the speed of generic entry. Health Serv. Res. 1997, 32 (1), 87-101.
85. Frank, R. G.; Salkever, D. S., Generic entry and the pricing of pharmaceuticals. J. Econ. Manage. Strat. 1997, 6 (1), 75-90.
86. Noor, W., The 2013 pharm exec top 50. Pharmaceutical Executive magazine 2013, 1-3.
87. Lafont, O., From the willow to aspirin. Rev. Hist. Pharm. 2007, 55 (354), 209-216.
88. Levesque H Fau - Lafont, O.; Lafont, O., Aspirin throughout the ages: a historical review. Rev. Med. Interne. 2000, 21, Supplement 1, 8S-17S
89. Haas, H., History of antipyretic analgesic therapy. Am. J. Med. 1983, 75 (5), 1-3.
90. Heymann, E.; Krisch, K.; Büch, H.; Buzello, W., Inhibition of phenacetin- and acetanilide-induced methemoglobinemia in the rat by the carboxylesterase inhibitor Bis-[p-nitrophenyl] phosphate. Biochem. Pharmacol. 1969, 18 (4), 801-811.
91. Lester, D.; Greenberg, L. A.; Carroll, R. P., The metabolic fate of acetanilid and other aniline derivatives: II. major metabolites of acetanilid appearing in the blood. J. Pharmacol. Exp. Ther. 1947, 90 (1), 68-75.
92. Brodie, B. B.; Axelrod, J., The estimation of acetanilide and its metabolic products, aniline, N-acetyl p-aminophenol and p-aminophenol (free and total conjugated) in biological fluids and tissues. J. Pharmacol. Exp. Ther. 1948, 94 (1), 22-28.
93. Silverman, M.; Lydecker, M.; Lee, P. R., Bad Medicine: The Prescription Drug Industry in the Third World. Stanford University Press, California, 1992; Chapter 5, pp 88-90.
94. Jones, R., Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am. J. Med. 2001, 110 (1A), 4S-7S.
95. Ameer, B.; Greenblatt, D. J., Acetaminophen. Ann. Intern. Med. 1977, 87 (2), 202-209.
96. Krenzelok, E. P., The FDA acetaminophen advisory committee meeting – what is the future of acetaminophen in the United States? The perspective of a committee member. Clin. Toxicol. 2009, 47 (8), 784-789.
97. Al-Zoubi, N.; Koundourellis, J. E.; Malamataris, S., FT-IR and Raman spectroscopic methods for identification and quantitation of orthorhombic and monoclinic paracetamol in powder mixes. J. Pharm. Biomed. Anal. 2002, 29 (3), 459-467.
98. Peterson, M. L.; Morissette, S. L.; McNulty, C.; Goldsweig, A.; Shaw, P.; LeQuesne, M.; Monagle, J.; Encina, N.; Marchionna, J.; Johnson, A.; Gonzalez-Zugasti, J.; Lemmo, A. V.; Ellis, S. J.; Cima, M. J.; Almarsson, Ö., Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. J. Am. Chem. Soc. 2002, 124 (37), 10958-10959.
99. Di Martino, P.; Conflant, P.; Drache, M.; Huvenne, J. P.; Guyot-Hermann, A. M., Preparation and physical characterization of forms II and III of paracetamol. J. Therm. Anal. Calorim. 1997, 48 (3), 447-458.
100. Moynihan, H. A.; O’Hare, I. P., Spectroscopic characterisation of the monoclinic and orthorhombic forms of paracetamol. Int. J. Pharm. 2002, 247 (1–2), 179-185.
101. Davenport, K. G.; Hilton, C. B., Process for producing N-acyl-hydroxy aromatic amines. US patent4524217, 1985.
102. Venneri, F., Fast, high-efficiency quantitative synthesis of paracetamol. EU patent 2266949, 2010.
103. Sander, J. R. G.; Bučar, D.-K.; Henry, R. F.; Baltrusaitis, J.; Zhang, G. G. Z.; MacGillivray, L. R., A red zwitterionic co-crystal of acetaminophen and 2,4-pyridinedicarboxylic acid. J. Pharm. Sci. 2010, 99 (9), 3676-3683.
104. Ålander, E. M.; Uusi-Penttilä, M. S.; Rasmuson, Å. C., Agglomeration of paracetamol during crystallization in pure and mixed solvents. Ind. Eng. Chem. Res. 2003, 43 (2), 629-637.
105. Uusi-Penttilä, M. S.; Rasmuson, Å. C., Experimental study for agglomeration behaviour of paracetamol in acetone–toluene–water systems. Chem. Eng. Res. Des. 2003, 81 (4), 489-495.
106. Pawar, A.; Paradkar, A.; Kadam, S.; Mahadik, K., Crystallo-co-agglomeration: A novel technique to obtain ibuprofen-paracetamol agglomerates. AAPS PharmSciTech 2004, 5 (3), 57-64.
107. Gao, Y.; Olsen, K. W., Molecular dynamics of drug crystal dissolution: simulation of acetaminophen form I in water. Mol. Pharmaceutics 2013, 10 (3), 905-917.
108. Lee, T.; Hung, S. T.; Kuo, C. S., Polymorph farming of acetaminophen and sulfathiazole on a chip. Pharm. Res. 2006, 23 (11), 2542-2555.
109. Lee, T.; Kuo, C. S.; Chen, Y. H., Solubility, polymorphism, crystallinity, and crystal habit of acetaminophen and ibuprofen by initial solvent screening. Pharm. Technol. 2006, 30 (10) 72-92.
110. Lee,T.; Chang, G. D., Engineering processing properties of acetaminophen by cosolvent screening. Pharm. Technol. 2010, 34 (8), 61-68.
111. Lee, T.; Hsu, F. B., A cross-performance relationship between Carr’s index and dissolution rate constant: the study of acetaminophen batches. Drug Dev. Ind. Pharm. 2007, 33 (11), 1273-1284.
112. Lee, T.; Hou, H. J.; Hsieh, H. Y.; Su, Y. C.; Wang, Y. W.; Hsu, F. B., The prediction of the dissolution rate constant by mixing rules: The study of acetaminophen batches. Drug Dev. Ind. Pharm. 2008, 34 (5), 522-535.
Chapter 2
1. Settle, F. A., Handbook of Instrumental Techniques for Analytical Chemistry. 1st Ed.; Prentice Hall PTR, New Jersey, 1997; Chapter 1, pp 1-15.
2. Boldyreva, E.; Drebushchak, V.; Paukiv, I.; Kovalevskaya, Y.; Drebushchak, T., DSC and adiabatic calorimetry study of the polymorphs of paracetamol. J. Therm. Anal. Calorim. 2004, 77 (2), 607-623.
3. Skoog, D. A.; Holler, F. J.; Nieman, T. A., Principle of Instrumental Analysis. 5th Ed.; Brooks/Cole, Canada, 1997; Chapter 31, pp 801-807.
4. Clas, S. D.; Dalton, C. R.; Hancock, B. C., Differential scanning calorimetry:
applications in drug development. Pharm. Sci. Technol. Today, 1999, 2 (8), 311-320.
5. Yu, L.; Reutzel, S. M.; Stephenson, G. A., Physical characterization of polymorphic drugs: an integrated characterization strategy. Pharm. Sci. Technol. Today, 1998, 1 (3), 118-127.
6. Skoog, D. A.; Holler, F. J.; Nieman, T. A., Principle of Instrumental Analysis. 5th Ed.; Brooks/Cole, Canada, 1997; Chapter 16, pp 392-396.
7. Skoog, D. A.; Holler, F. J.; Crouch, S. R., Principle of Instrumental Analysis. 6th Ed.; Thomson Higher Education, Belmont; Chapter 17, p 405.
8. Bauer-Brandl, A., Polymorphic transitions of cimetidine during manufacture of solid dosage forms. Int. J. Pharm., 1996, 140 (2), 195-206.
9. Koller, L. R., Ultraviolet Radiation. 2nd Ed.; John Wiley and Sons, New York, 1952; Chapter 1, pp 1-20.
10. Skoog, D. A.; Holler, F. J.; Nieman, T. A., Principles of Instrumental Analysis, 5th Ed.; Brooks/Cole, Canada, 1997; Chapter 13, pp 300-328.
11. Skoog, D. A.; Holler, F. J.; Crouch, S. R., Principles of Instrumental Analysis. 5th Ed.; Brooks/Cole, Canada, 1997; Chapter 14, pp 329-354.
12.http://computing.dcu.ie/~humphrys/Notes/Networks/physical.wireless.html
13. Ayora Canada M. J.; Reguera M. I. P.; Mo. Diaz A.; Vallvey L. F. C., Solid-phase UV spectroscopic multisensor for thesimultaneous determination of caffeine, dimenhydrinate and acetaminophen by using partial least squares multicalibration. Talanta, 1999, 49 (3), 691-701.
14. http://www.cem.msu.edu/~reusch/VirtualText/Spectrpy/UV-Vis/uvspec.htm.
15. Amelinckx, S.; Dyck, D. V.; Landuyt, J. V.; Tendeloo, G.V., Handbook of Microscopy: Applications in Materials Science, Solid-State Physics and Chemistry Applications, Wiley-VCH, New York, 2008; Chapter 7, pp 293-320.
16. Haleblian, J.; McCrone, W., Pharmaceutical Applications of Polymorphism. J. Pharm. Sci. 1969, 58 (8), 911-929.
17. Rasenack, N.; Muller, B. W., Crystal Habit and Tableting Behavior. Int. J. Pharm. 2002, 244 (1-2), 45-47.
18. Larhrib, N.; Martin, G. P.; Marriott, C.; Prime, D., The influence of carrier and drug morphology on drug delivery from dry powder formations. Int. J. Pharm. 2003, 257 (1-2), 283-296.
19. Skoog, D. A.; Holler, F. J.; Crouch, S. R. Principle of Instrumental Analysis, 5th Ed.; Brooks/Cole, Canada, 1997, Chapter 21, pp 550-553.
20. Reed-hill, R. E.; Abbaschian R., Physical Metallurgy Principles. 3rd Ed.; CL-Engineering, Boston, 1992; Chapter 2, pp 53-60.
21. http://cmrf.research.uiowa.edu/scanning-electron-microscopy
22. Skoog, D. A.; Holler, F. J.; Crouch, S. R. Principle of Instrumental Analysis. 5th Ed.; Brooks/Cole, Canada, 1997; Chapter 12, pp 272-296.
23. Padden, B. E.; Zell, M. T.; Schroeder, S. A.; Grant, D. J. W.; Munson, E. J., Comparison of solid state 13C NMR spectroscopy and powder X-ray diffraction for analyzing mixtures of polymorphs of neotame. Anal. Chem. 1999, 71 (16), 3325-3331.
24. Rodrıguez-Spong, B.; Price, C. P.; Jayasankar, A.; Matzger A. J.; Rodrıguez-Hornedo, N., General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv. Drug Deliver. Rev. 2004, 56 (3), 241-274.
25. Miura, H.; Ushio, T.; Nagai, K.; Fujimoto, D; Lepp, Z.; Takahashi, H.; Tamura, R., Crystallization of a desired metastable polymorph by pseudoseeding, crystal structure solution from its powder X-ray diffraction data, and confirmation of polymorphic transition. Cryst. Growth Des. 2003, 3 (6), 959-965.
26. Colle, M.; Gmeiner, J.; Milius, W.; Hillebrecht, H.; Brutting, W., Preparation and characterization of blue-lumincent tris(8-hydroxyquinoline)-aluminum (Alq3). Adv. Funct. Mater. 2003, 13 (2), 108-112.
Chapter 3
1. Hinz, D. C., Process analytical technologies in the pharmaceutical industry: the FDA’s PAT initiative. Anal. Bioanal. Chem. 2006, 384 (5), 1036-1042.
2. Kim, S.; Lotz, B.; Lindrud, M.; Girard, K.; Moore, T.; Nagarajan, K.; Alvarez, M.; Lee, T.; Nikfar, F.; Davidovich, M.; Srivastava, S.; Kiang, S., Control of the particle properties of a drug substance by crystallization engineering and the effect on drug product formulation. Org. Process Res. Dev. 2005, 9 (6), 894-901.
3. Kadam, S. S.; Vissers, J. A. W.; Forgione, M.; Geertman, R. M.; Daudey, P. J.; Stankiewicz, A. I.; Kramer, H. J. M., Rapid crystallization process development strategy from lab to industrial scale with PAT tools in skid configuration. Org. Process Res. Dev. 2012, 16 (5), 769-780.
4. Peterson, M. L.; Morissette, S. L.; McNulty, C.; Goldsweig, A.; Shaw, P.; LeQuesne, M.; Monagle, J.; Encina, N.; Marchionna, J.; Johnson, A.; Gonzalez-Zugasti, J.; Lemmo, A. V.; Ellis, S. J.; Cima, M. J.; Almarsson, Ö., Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. J. Am. Chem. Soc. 2002, 124 (37), 10958-10959.
5. Parkin, A.; Parsons, S.; Pulham, C. R., Paracetamol monohydrate at 150 K. Acta Crystallogr. Sect. E: Struct. Rep. Online 2002, 58 (12), 1345-1347.
6. Wang, S.-L.; Lin, S.-Y.; Wei, Y.-S., Transformation of metastable forms of acetaminophen studied by thermal fourier transform infrared (FT-IR) microspectroscopy. Chem. Pharm. Bull. 2002, 50 (2), 153-156.
7. Davenport, K. G.; Hilton, C. B., Process for producing N-acyl-hydroxy aromatic amines. US patent 4524217, 1985.
8. Venneri, F., Fast, high-efficiency quantitative synthesis of paracetamol. Euro patent 2266949, 2010.
9. Frank, E. Paracetamol – A Curriculum Resource. Royal Society of Chemistry, London, 2002; p 5.
10. Fritch, J. R.; Fruchey, S. O.; Horlenko, T.; Aguilar, D. A.; Hilton, C. B.; Snyder, P. S.; William, J., Production of acetaminophen. US patent 5155273, 1992.
11. Ålander, E. M.; Uusi-Penttilä, M. S.; Rasmuson, Å. C., Agglomeration of paracetamol during crystallization in pure and mixed solvents. Ind. Eng. Chem. Res. 2003, 43 (2), 629-637.
12. Lee, T.; Su, Y. C.; Hou, H. J.; Hsieh, H. Y., Spherical crystallization for lean solid-dose manufacturing (Part I). Pharm. Technol. 2010, 34 (3), 72-75.
13. Lee, T.; Su, Y. C.; Hou, H. J.; Hsieh, H. Y., Spherical crystallization for lean solid-dose manufacturing (Part II). Pharm. Technol. 2010, 34 (4), 88-103.
14. Ålander, E. M.; Rasmuson, Å. C., Mechanisms of crystal agglomeration of paracetamol in acetone−water mixtures. Ind. Eng. Chem. Res. 2005, 44 (15), 5788-5794.
15. Alvarez, A. J.; Myerson, A. S., Continuous plug flow crystallization of pharmaceutical compounds. Cryst. Growth Des. 2010, 10 (5), 2219-2228.
16. Méndez del Río, J. R.; Rousseau, R. W., Batch and tubular-batch crystallization of paracetamol: crystal size distribution and polymorph formation. Cryst. Growth Des. 2006, 6 (6), 1407-1414.
17. Denbigh, K. G., Velocity and yield in continuous reaction systems. Trans. Faraday Soc. 1944, 40, 352-373.
18. MacLeod, C. S.; Muller, F. L., On the fracture of pharmaceutical needle-shaped crystals during pressure filtration: case studies and mechanistic understanding. Org. Process Res. Dev. 2012, 16 (3), 425-434.
19. Burgbacher, J.; Wiss, J., Industrial applications of online monitoring of drying processes of drug substances using NIR. Org. Process Res. Dev. 2008, 12 (2), 235-242.
20. McLoughlin, C. M.; McMinn, W. A. M.; Magee, T. R. A., Microwave drying of pharmaceutical powders. Food Bioprod. Proc. 2000, 78 (2), 90-96.
21. Gao, Y.; Olsen, K. W., Molecular dynamics of drug crystal dissolution: simulation of acetaminophen form I in water. Mol. Pharm. 2013, 10 (3), 905-917.
22. Bastin, R. J.; Bowker, M. J.; Slater, B. J., Salt selection and optimisation procedures for pharmaceutical new chemical entities. Org. Process Res. Dev. 2000, 4 (5), 427-435.
23. Black, S. N.; Collier, E. A.; Davey, R. J.; Roberts, R. J., Structure, solubility, screening, and synthesis of molecular salts. J. Pharm. Sci. 2007, 96 (5), 1053-1068.
24. Hilden, L. R.; Morris, K. R., Physics of amorphous solids. J. Pharm. Sci. 2004, 93 (1), 3-12.
25. Hilfiker, R.; Berghausen, J.; Blatter, F.; Burkhard, A.; De Paul, S. M.; Freiermuth, B.; Geoffroy, A.; Hofmeier, U.; Marcolli, C.; Siebenhaar, B.; Szelagiewicz, M.; Vit, A.; von Raumer, M., Polymorphism - integrated approach from high-throughput screening to crystallization optimization. J. Therm. Anal. Calorim. 2003, 73 (2), 429-440.
26. Blagden, N.; Davey, R. J., Polymorph selection: challenges for the future? Cryst. Growth Des. 2003, 3 (6), 873-885.
27. Lee, T.; Hung, S. T.; Kuo, C. S., Polymorph farming of acetaminophen and sulfathiazole on a chip. Pharm. Res. 2006, 23 (11), 2542-2555.
28. Singhal, D.; Curatolo, W., Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. 2004, 56 (3), 335-347.
29. Vishweshwar, P.; McMahon, J. A.; Peterson, M. L.; Hickey, M. B.; Shattock, T. R.; Zaworotko, M. J., Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients. Chem. Commun. 2005, 2005 (36), 4601-4603.
30. Zhang, G. G. Z.; Henry, R. F.; Borchardt, T. B.; Lou, X., Efficient co-crystal screening using solution-mediated phase transformation. J. Pharm. Sci. 2007, 96 (5), 990-995.
31. Koshima, H.; Miyauchi, M., Polymorphs of a cocrystal with achiral and chiral structures prepared by pseudoseeding: tryptamine/hydrocinnamic acid. Cryst. Growth Des. 2001, 1 (5), 355-357.
32. Chen, J.-F.; Zhou, M.-Y.; Shao, L.; Wang, Y.-Y.; Yun, J.; Chew, N. Y. K.; Chan, H.-K., Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int. J. Pharm. 2004, 269 (1), 267-274.
33. Lee, T.; Zhang, C. W., Dissolution enhancement by bio-inspired mesocrystals: the study of racemic (R,S)-(±)-sodium ibuprofen dihydrate. Pharm. Res. 2008, 25 (7), 1563-1571.
34. Serajuddin, A. T. M., Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88 (10), 1058-1066.
35. Berglund, K. A., HandBook of Industrial Crystallization. Butterworth-Heinemann, Boston, 1993; Chapter 4, pp 89-93.
36. Rohani, S., Nucleation, growth, and aggregation kinetics of potassium chloride from a continuous mixed-suspension mixed-product removal cooling crystallizer. Sep. Technol. 1993, 3 (2), 99-105.
37. Hounslow, M. J., Nucleation, growth, and aggregation rates from steady-state experimental data. AIChE J. 1990, 36 (11), 1748-1752.
38. Bohlin, M.; Rasmuson, Å. C., Modeling of growth rate dispersion in batch cooling crystallization. AIChE J. 1992, 38 (12), 1853-1863.
39. Cheon, Y.-H.; Kim, K.-J.; Kim, S.-H. A study on crystallization kinetics of pentaerythritol in a batch cooling crystallizer. Chem. Eng. Sci. 2005, 60 (17), 4791-4802.
40. Lawton, S.; Steele, G.; Shering, P.; Zhao, L.; Laird, I.; Ni, X.-W., Continuous crystallization of pharmaceuticals using a continuous oscillatory baffled crystallizer. Org. Process Res. Dev. 2009, 13 (6), 1357-1363.
41. Uusi-Penttilä, M. S.; Rasmuson, Å. C., Experimental study for agglomeration behaviour of paracetamol in acetone–toluene–water systems. Chem. Eng. Res. Des. 2003, 81 (4), 489-495.
42. McCabe, W. L.; Smith, J. C.; Harriott, P., Unit Operations of Chemical Engineering. 7th Ed.; McGraw-Hill, New York, 2005; Chapter 29, p 1021.
43. McCabe, W. L.; Smith, J. C.; Harriott, P., Unit Operations of Chemical Engineering. 7th Ed.; McGraw-Hill, New York, 2005; Chapter 24, pp 796-835.
44. Lee, T.; Hsu, F. B., A cross-performance relationship between carr’s index and dissolution rate constant: the study of acetaminophen batches. Drug Dev. Ind. Pharm. 2007, 33 (11), 1273-1284.
Chapter 4
1. Lee, T.; Hsu, F. B., A cross-performance relationship between carr’s index and dissolution rate constant: the study of acetaminophen batches. Drug Dev Ind Pharm 2007, 33 (11), 1273-1284.
2. Alvarez, A. J.; Myerson, A. S., Continuous plug flow crystallization of pharmaceutical compounds. Cryst. Growth Des. 2010, 10 (5), 2219-2228.
3. Bogdan, A. R.; Poe, S. L.; Kubis, D. C.; Broadwater, S. J.; McQuade, D. T., The continuous-flow synthesis of ibuprofen. Angew. Chem. Int. Ed. 2009, 48 (45), 8547-8550.
Appendix
1. Lang, M.; Grzesiak, A. L.; Matzger, A. J., The use of polymer heteronuclei for crystalline polymorph selection. J. Am. Chem. Soc. 2002, 124 (50), 14834-14835.
2. Peterson, M. L.; Morissette, S. L.; McNulty, C.; Goldsweig, A.; Shaw, P.; LeQuesne, M.; Monagle, J.; Encina, N.; Marchionna, J.; Johnson, A.; Gonzalez-Zugasti, J.; Lemmo, A. V.; Ellis, S. J.; Cima, M. J.; Almarsson, Ö., Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. J. Am. Chem. Soc. 2002, 124 (37), 10958-10959.
3. Di Martino, P.; Guyot-Hermann, A. M.; Conflant, P.; Drache, M.; Guyot, J. C., A new pure paracetamol for direct compression: the orthorhombic form. Int. J. Pharm. 1996, 128 (1–2), 1-8.
4. Nichols, G.; Frampton, C. S., Physicochemical characterization of the orthorhombic polymorph of paracetamol crystallized from solution. J. Pharm. Sci. 1998, 87 (6), 684-693.
5. Thomas, L. H.; Wales, C.; Zhao, L.; Wilson, C. C., Paracetamol form II: an elusive polymorph through facile multicomponent crystallization routes. Cryst. Growth Des. 2011, 11 (5), 1450-1452.
6. Wang, S.-L.; Lin, S.-Y.; Wei, Y.-S., Transformation of metastable forms of acetaminophen Studied by thermal fourier transform infrared (FT-IR) microspectroscopy. Chem. Pharm. Bull. 2002, 50 (2), 153-156.
7. Al-Zoubi, N.; Koundourellis, J. E.; Malamataris, S., FT-IR and Raman spectroscopic methods for identification and quantitation of orthorhombic and monoclinic paracetamol in powder mixes. J. Pharm. Biomed. Anal. 2002, 29 (3), 459-467.
8. Di Martino, P.; Conflant, P.; Drache, M.; Huvenne, J. P.; Guyot-Hermann, A. M., Preparation and physical characterization of forms II and III of paracetamol. J. Therm. Anal. Calorim. 1997, 48 (3), 447-458.
9. Moynihan, H. A.; O’Hare, I. P., Spectroscopic characterisation of the monoclinic and orthorhombic forms of paracetamol. Int. J. Pharm. 2002, 247 (1–2), 179-185.
10. Zimmermann, B.; Baranović, G., Thermal analysis of paracetamol polymorphs by FT-IR spectroscopies. J. Pharm. Biomed. Anal. 2011, 54 (2), 295-302.
11. Sacchetti, M., Thermodynamic analysis of DSC data for acetaminophen polymorphs. J. Therm. Anal. Calorim. 2000, 63 (2), 345-350.
12. Lin, S. Y.; Wang, S. L.; Cheng, Y. D., Thermally induced structural changes of acetaminophen in phase transition between the solid and liquid states monitored by combination analysis of FT-IR/DSC microscopic system. J. Phys. Chem. Solids 2000, 61 (11), 1889-1893. |